By Salamander Davoudi JULY 10 2007 Print this page Shares in Northwest Biotherapeutics, which jumped 34 per cent on Monday after the company said it had received approval for its brain cancer vaccine in Switzerland, leapt another 54 per cent on Tuesday.
“This company has transformed the prospects for brain cancer patients overnight,” said Navid Malik, analyst at Collins Stewart, Northwest’s house broker. “DCVax will be available to European citizens in months.”